The U.S. Food and Drug Administration issued a warning letter to Juul Labs Inc. over the company’s marketing practices for e-cigarettes.
An Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for the company’s part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum substantially less than investors expected, driving up J&J shares.
Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.
Johnson & Johnson and the company’s DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants.
Maryland charged Insys Therapeutics Inc. with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.
Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.
New Jersey sued Purdue Pharma LP, maker of the chronic pain medication OxyContin, accusing the company of engaging in deceptive marketing practices that contributed to what it called the state’s opioid crisis.